Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
EHRA 24: AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease
Author(s): Laurent Fiorina Added: 1 year ago
EHRA 24 - In this short interview, we are joined by Dr Laurent Fiorina (Cardiovascular Institute Paris-Sud (ICPS), FR) joins us to discuss the findings from a clinical investigation into diagnosing conduction tissue disease using an AI-enabled single-lead coronary ECG device.This observational, prospective clinical trial aims to investigate the performance of an artificial intelligence algorithm… View more

Imaging & Diagnostics

Electrophysiology & Arrhythmia
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 11 months ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
CardioNerds @AHA23: An Extended Duration Short-Interfering RNA Targeting Lp(a)
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 2 years ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more

Heart Failure

Prevention & Chronic Conditions
EHRA 24: FIH Novel PFA Catheter for PVI
Author(s): Vivek Reddy Added: 1 year ago
EHRA 24 - We interview Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, US) on a first-in-human clinical trial of a novel conformable "single-shot" pulsed field ablation (PFA) catheter for pulmonary vein isolation (PVI).This single arm trial aimed to assess the safety and efficacy of PVI using an 8Fr PFA catheter (SpherePVI, Affera Inc) in 30 patients across three centers.Interview… View more

Electrophysiology & Arrhythmia
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 11 months ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure
Post-COVID-19 Myocarditis Identified using CMR
Author(s): Reynald Evan R Tugade , Nyssa Elline Palileo , Danica Ann Leycano , et al Added: 1 year ago

Imaging & Diagnostics
Drug-eluting Balloons: Experience from Central India
Author(s): Ajinkya Mahorkar , Virag Mahorkar , Uday Mahorkar , et al Added: 11 months ago

Intervention

Prevention & Chronic Conditions
Telomere Biology in Cardiovascular Disease
Author(s): Xian Wen Tan , Alan Yean Yip Fong , Siaw San Hwang Added: 2 years ago

Prevention & Chronic Conditions
ESC 25: The KARDIA-3 Study
Author(s): Neha Pagidipati Added: 6 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more

Prevention & Chronic Conditions